This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Several late-stage pipeline products have the potential to address some of these unmet needs
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
Franson will help biopharma clients design a phased approach to inform and execute clinical development plans
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Subscribe To Our Newsletter & Stay Updated
